Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Leases (2018 - 2025)

Historic Leases for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Q3 2025 value amounting to $40.7 million.

  • Rocket Pharmaceuticals' Leases fell 502.07% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year decrease of 502.07%. This contributed to the annual value of $42.4 million for FY2024, which is 483.86% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Leases of $40.7 million as of Q3 2025, which was down 502.07% from $41.3 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Leases high stood at $50.3 million for Q1 2021, and its period low was $200000.0 during Q1 2023.
  • Moreover, its 5-year median value for Leases was $45.1 million (2023), whereas its average is $43.1 million.
  • In the last 5 years, Rocket Pharmaceuticals' Leases tumbled by 9958.29% in 2023 and then surged by 2188950.0% in 2024.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Leases stood at $48.5 million in 2021, then fell by 3.75% to $46.7 million in 2022, then fell by 4.6% to $44.5 million in 2023, then dropped by 4.84% to $42.4 million in 2024, then fell by 3.81% to $40.7 million in 2025.
  • Its Leases stands at $40.7 million for Q3 2025, versus $41.3 million for Q2 2025 and $41.8 million for Q1 2025.